• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.

出版信息

Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.

PMID:25768993
Abstract
摘要

相似文献

1
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.增加利妥昔单抗（R）剂量可消除侵袭性CD20+B细胞淋巴瘤老年男性患者增加的风险并改善预后：德国淋巴瘤研究组（DSHNHL）的SEXIE-R-CHOP-14试验
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.
2
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.老年弥漫性大B细胞淋巴瘤患者中，CHOP化疗联合利妥昔单抗与单纯CHOP化疗的比较。
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
3
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).在老年弥漫性大B细胞淋巴瘤患者中，R-CHOP诱导化疗四个周期后进行利妥昔单抗巩固治疗：淋巴瘤生存改善联盟研究（CISL）
Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.
4
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.硼替佐米联合 R-CHOP 方案治疗初治侵袭性非霍奇金淋巴瘤的Ⅰ期临床试验。
Cancer. 2010 Dec 1;116(23):5432-9. doi: 10.1002/cncr.25509. Epub 2010 Jul 27.
5
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.在接受R-CHOP治疗的大量连续老年弥漫性大B细胞淋巴瘤（DLBCL）患者队列中，男性是生存和复发情况较差的独立预测因素。
Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24.
6
Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.利妥昔单抗对弥漫性大 B 细胞淋巴瘤患者治疗结局的影响：一项基于人群的分析。
Br J Haematol. 2012 Aug;158(4):481-8. doi: 10.1111/j.1365-2141.2012.09177.x. Epub 2012 Jun 5.
7
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.利妥昔单抗联合环磷酰胺、长春新碱和泼尼松（R-CVP）与利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）用于80岁及以上弥漫性大B细胞淋巴瘤老年患者的比较。
Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.
8
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.利妥昔单抗治疗弥漫性大B细胞淋巴瘤的优化：增加老年男性患者的剂量
Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8.
9
Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.利妥昔单抗联合环磷酰胺/阿霉素/长春新碱/泼尼松（CHOP）治疗干燥综合征相关B细胞侵袭性非霍奇金淋巴瘤。
Rheumatology (Oxford). 2004 Aug;43(8):1050-3. doi: 10.1093/rheumatology/keh248. Epub 2004 Jun 8.
10
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.ACVBP 强化化疗联合利妥昔单抗对比标准 CHOP 联合利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤（LNH03-2B）：一项开放标签、随机、3 期临床试验。
Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.

引用本文的文献

1
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.抗癌药物药代动力学中的性别差异：一项系统评价。
ESMO Open. 2024 Dec;9(12):104002. doi: 10.1016/j.esmoop.2024.104002. Epub 2024 Dec 10.
2
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.阿托伐他汀与安慰剂对接受R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者疗效的影响。
Leuk Lymphoma. 2024 Jun;65(6):783-788. doi: 10.1080/10428194.2024.2317343. Epub 2024 Feb 21.
3
Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.
通过PET/CT评估的代谢生物标志物可预测弥漫性大B细胞淋巴瘤患者的性别特异性纵向预后。
Cancers (Basel). 2022 Jun 14;14(12):2932. doi: 10.3390/cancers14122932.
4
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.奥滨尤妥珠单抗暴露对一线免疫化疗治疗滤泡性淋巴瘤临床结局的影响。
Br J Clin Pharmacol. 2019 Jul;85(7):1495-1506. doi: 10.1111/bcp.13920. Epub 2019 May 17.
5
Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.弥漫性大B细胞淋巴瘤一线治疗的演变：简要综述与近期进展
F1000Res. 2016 Aug 8;5. doi: 10.12688/f1000research.8790.1. eCollection 2016.
6
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.美国滤泡性淋巴瘤患者中男性与女性之间的疾病、治疗及预后差异
Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401. Epub 2016 May 24.
7
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?利妥昔单抗维持治疗弥漫性大B细胞淋巴瘤：XY是最重要的变量吗？
Haematologica. 2015 Jul;100(7):853-5. doi: 10.3324/haematol.2015.129924.
8
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.利妥昔单抗用于一线缓解期侵袭性B细胞淋巴瘤患者的维持治疗：随机NHL13试验结果
Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.
9
Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy.性别在非霍奇金淋巴瘤中重要吗？流行病学、临床行为及治疗方面的差异。
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0038. doi: 10.5041/RMMJ.10172. eCollection 2014 Oct.